Kytril (Granisetron Hydrochloride)

Kytril, a selective 5‑HT3 receptor antagonist, is employed to control nausea and vomiting associated with specific treatment pathways.

• Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of nausea and vomiting caused by cytotoxic chemotherapy.
• Postoperative nausea and vomiting: prevents nausea and vomiting that can occur after surgical procedures.
• Radiation‑induced nausea and vomiting: helps control nausea and vomiting related to radiotherapy treatments.

• Granisetron works by selectively blocking peripheral and central 5‑HT3 receptors, which are activated by serotonin released during chemotherapy, radiation, or surgical stress. By inhibiting these receptors, the drug interrupts the neural signaling that triggers the vomiting reflex, thereby reducing nausea and emesis.

Common Side Effects

• Headache: mild to moderate pain often occurring shortly after administration.
• Constipation: reduced bowel movements that may require dietary adjustment.
• Dizziness: transient sensation of light‑headedness.
• Fatigue: feeling unusually tired or weak.

Serious or Rare Side Effects

• Cardiac arrhythmia: irregular heart rhythm, especially in patients with pre‑existing cardiac disease.
• Severe allergic reaction (anaphylaxis): rapid onset of hives, swelling, and breathing difficulty.
• QT interval prolongation: potential for serious ventricular arrhythmias.
• Serotonin syndrome: rare condition with agitation, hyperthermia, and neuromuscular abnormalities.

Before using Kytril, consider the following safety measures.

• Cardiac assessment: evaluate QT interval and avoid use in patients with known prolongation.
• Hepatic function: adjust use in severe liver impairment.
• Electrolyte balance: correct abnormalities such as hypokalemia before administration.
• Concomitant serotonergic agents: review other medications that affect serotonin pathways.
• Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kytril may interact with several drug classes; monitoring is essential.

Major Interactions (Avoid)

• Apomorphine: concurrent use can cause severe hypotension and loss of consciousness.
• Other 5‑HT3 antagonists: may lead to antagonistic effects and reduced efficacy.
• QT‑prolonging agents (e.g., quinidine, haloperidol): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise granisetron plasma levels.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug exposure.
• Additional antiemetics (e.g., ondansetron, metoclopramide): may require dose adjustment.